Asthma Therapy - Biologics/Monoclonal Antibodies

Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic st...

Asthma Therapy - Biologics/Monoclonal Antibodies refers to a specialized therapeutic drug grouping consisting of targeted monoclonal antibodies indicated as add-on maintenance treatment for moderate-to-severe, uncontrolled asthma Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic st...

Rather than providing broad immunosuppression, these agents function by selectively binding and neutralizing specific inflammatory mediators—such as immunoglobulin E (anti-IgE), interleukins 4, 5, and 13 (anti-IL-5, anti-IL-5 receptor, and anti-IL-4/IL-13), or thymic stromal lymphopoietin (anti-TSLP)—thereby halting key cascades driving chronic airway inflammation

Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes

Their principal clinical role is to diminish exacerbations, enhance lung function, and reduce reliance on oral corticosteroids in severe eosinophilic or allergic asthma phenotypes

Several agents within this class also extend therapeutically to overlapping type 2 inflammatory conditions, including chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and atopic dermatitis